1. Home
  2. RBNE vs PULM Comparison

RBNE vs PULM Comparison

Compare RBNE & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RBNE

Robin Energy Ltd.

HOLD

Current Price

$0.77

Market Cap

15.8M

ML Signal

HOLD

Logo Pulmatrix Inc.

PULM

Pulmatrix Inc.

HOLD

Current Price

$4.43

Market Cap

14.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RBNE
PULM
Founded
2024
2003
Country
Cyprus
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.8M
14.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
RBNE
PULM
Price
$0.77
$4.43
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
219.0K
9.5K
Earning Date
10-23-2025
10-16-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$3,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$134.88
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.67
$3.90
52 Week High
$24.65
$10.40

Technical Indicators

Market Signals
Indicator
RBNE
PULM
Relative Strength Index (RSI) 37.25 49.50
Support Level $0.85 $3.95
Resistance Level $0.89 $4.48
Average True Range (ATR) 0.06 0.32
MACD 0.02 0.01
Stochastic Oscillator 23.69 50.96

Price Performance

Historical Comparison
RBNE
PULM

About RBNE Robin Energy Ltd.

Robin Energy Ltd operates a tanker vessel that engages in the transportation of refined petroleum products using its Handysize product tanker.

About PULM Pulmatrix Inc.

Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).

Share on Social Networks: